{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:11:39Z","timestamp":1785208299420,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1112,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["REBIRTHI\/II-ZN3440"],"award-info":[{"award-number":["REBIRTHI\/II-ZN3440"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nieders\u00e4chsisches Vorab","award":["VWZN3452"],"award-info":[{"award-number":["VWZN3452"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["RI 2531\/2-2"],"award-info":[{"award-number":["RI 2531\/2-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["HI 842\/10-2"],"award-info":[{"award-number":["HI 842\/10-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"publisher","award":["19CVD02"],"award-info":[{"award-number":["19CVD02"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["REBIRTHI\/II\u2010ZN3440"],"award-info":[{"award-number":["REBIRTHI\/II\u2010ZN3440"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["Nieders\u00e4chsischesVorab\u2010VWZN3452"],"award-info":[{"award-number":["Nieders\u00e4chsischesVorab\u2010VWZN3452"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RI 2531\/2\u20102"],"award-info":[{"award-number":["RI 2531\/2\u20102"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HI 842\/10\u20102"],"award-info":[{"award-number":["HI 842\/10\u20102"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["19CVD02"],"award-info":[{"award-number":["19CVD02"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Peripartum cardiomyopathy (PPCM) is a rare heart disease, occurring in previously heart-healthy women during the last month of pregnancy or the first months after delivery due to left ventricular (LV) systolic dysfunction. A common pathomechanistic pathway of PPCM includes increased oxidative stress and the subsequent generation of a cleaved prolactin fragment (16 kDa PRL), which promotes the onset of heart failure (HF) in a microRNA (miR)-146a-dependent manner. Inhibition of prolactin secretion with the dopamine D2 receptor (D2R) agonist bromocriptine combined with standard HF therapy supports cardiac recovery. This study examined whether treatment with the more selective D2R agonist cabergoline prevents HF development in an experimental PPCM mouse model and might be used as an alternative treatment regime for PPCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Postpartum (PP) female PPCM-prone mice with a cardiomyocyte restricted STAT3-deficiency (\u03b1MHC-Cretg\/+; Stat3fl\/fl; CKO) were treated over two consecutive nursing periods with cabergoline (CKO Cab, 0.5 mg\/kg\/day) and were compared with bromocriptine treated CKO (CKO Br) and postpartum-matched WT and CKO mice. Cabergoline treatment in CKO PP mice preserved cardiac function [fractional shortening (FS): CKO Cab: 34.5 \u00b1 9.4% vs. CKO: 22.1 \u00b1 9%, P &amp;lt; 0.05] and prevented the development of cardiac hypertrophy, fibrosis, and inflammation as effective as bromocriptine therapy (FS: CKO Br: 33.4 \u00b1 5.6%). The myocardial up-regulation of the PPCM biomarkers plasminogen inhibitor activator 1 (PAI-1) and miR-146a were prevented by both cabergoline and bromocriptine therapy.<\/jats:p>\n                    <jats:p>A small cohort of three PPCM patients from the German PPCM Registry was treated with cabergoline (1 mg per week for 2 weeks, followed by 0.5 mg per week for another 6 weeks) due to a temporary unavailability of bromocriptine. All PPCM patients initially presented with a severely reduced LV ejection fraction (LVEF: 26 \u00b1 2%). However, at 6 months of follow-up, LV function (LVEF: 56 \u00b1 2%) fully recovered in all three PPCM patients, and no adverse events were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the experimental PPCM mouse model, the selective D2R agonist cabergoline prevents the onset of postpartum HF similar to bromocriptine. In PPCM patients, cabergoline treatment was safe and effective as all patients fully recovered. Cabergoline might serve as a promising alternative to bromocriptine. However, these findings are based on experimental data and a small case series and thus have to be interpreted with caution and should be validated in a larger clinical trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14210","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T06:53:05Z","timestamp":1666853585000},"page":"465-477","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cabergoline Treatment Promotes Myocardial Recovery in Peripartum Cardiomyopathy"],"prefix":"10.1093","volume":"10","author":[{"given":"Tobias J.","family":"Pfeffer","sequence":"first","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Haebel","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej","family":"Erschow","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuebra C.","family":"Yalman","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9062-4065","authenticated-orcid":false,"given":"Steven R.","family":"Talbot","sequence":"additional","affiliation":[{"name":"Institute for Laboratory Animal Science and Central Animal Facility, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Koenig","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Berliner","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Zwadlo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Scherr","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-9649","authenticated-orcid":false,"given":"Denise","family":"Hilfiker-Kleiner","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]},{"name":"Department of Cardiovascular Complications of Oncologic Therapies, Medical Faculty, Philipps University Marburg , Marburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-2275","authenticated-orcid":false,"given":"Melanie","family":"Ricke-Hoch","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2026012114123349100_ehf214210-bib-0001","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0002","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1172\/JCI64365","article-title":"MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy","volume":"123","author":"Halkein","year":"2013","journal-title":"J Clin Invest"},{"key":"2026012114123349100_ehf214210-bib-0003","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/cvr\/cvz252","article-title":"Peripartum cardiomyopathy: Basic mechanisms and hope for new therapies","volume":"116","author":"Ricke-Hoch","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026012114123349100_ehf214210-bib-0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cell.2006.12.036","article-title":"A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy","volume":"128","author":"Hilfiker-Kleiner","year":"2007","journal-title":"Cell"},{"key":"2026012114123349100_ehf214210-bib-0005","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/cvr\/cvz300","article-title":"In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles","volume":"116","author":"Ricke-Hoch","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026012114123349100_ehf214210-bib-0006","first-page":"349","article-title":"Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy","volume":"38","author":"Stapel","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114123349100_ehf214210-bib-0007","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehx355","article-title":"Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study","volume":"38","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114123349100_ehf214210-bib-0008","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/eurheartj\/ehaa455","article-title":"Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: An ESC EORP registry","volume":"41","author":"Sliwa","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114123349100_ehf214210-bib-0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11040","article-title":"Cardiac angiogenic imbalance leads to peripartum cardiomyopathy","volume":"485","author":"Patten","year":"2012","journal-title":"Nature"},{"key":"2026012114123349100_ehf214210-bib-0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00395-013-0366-9","article-title":"Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy","volume":"108","author":"Haghikia","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"2026012114123349100_ehf214210-bib-0011","first-page":"27","article-title":"The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: Insights from the BRO-HF retrospective cohort study. ESC","volume":"6","author":"Tremblay-Gravel","year":"2019","journal-title":"Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0012","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1093\/eurheartj\/ehx428","article-title":"Bromocriptine for the treatment of peripartum cardiomyopathy: Welcome on BOARD","volume":"38","author":"Arrigo","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114123349100_ehf214210-bib-0013","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ejhf.2133","article-title":"Risk stratification and management of women with cardiomyopathy\/heart failure planning pregnancy or presenting during\/after pregnancy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"23","author":"Sliwa","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006898","article-title":"ERBB4 and multiple MicroRNAs that target ERBB4 participate in pregnancy-related cardiomyopathy","volume":"14","author":"Feyen","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.RES.0000134921.50377.61","article-title":"Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury","volume":"95","author":"Hilfiker-Kleiner","year":"2004","journal-title":"Circ Res"},{"key":"2026012114123349100_ehf214210-bib-0016","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1002\/ehf2.13412","article-title":"Perhexiline treatment improves toxic effects of beta-adrenergic receptor stimulation in experimental peripartum cardiomyopathy","volume":"8","author":"Pfeffer","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93098","article-title":"Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression","volume":"2","author":"Thackeray","year":"2017","journal-title":"JCI Insight"},{"key":"2026012114123349100_ehf214210-bib-0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00395-020-00821-z","article-title":"Neuraminidase-1 promotes heart failure after ischemia\/reperfusion injury by affecting cardiomyocytes and invading monocytes\/macrophages","volume":"115","author":"Heimerl","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"2026012114123349100_ehf214210-bib-0019","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/eurjhf\/hfq120","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy","volume":"12","author":"Sliwa","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0020","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ejhf.1624","article-title":"Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: Low mortality, high cardiac recovery, but significant cardiovascular co-morbidities","volume":"21","author":"Moulig","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0021","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012114123349100_ehf214210-bib-0022","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012114123349100_ehf214210-bib-0023","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012114123349100_ehf214210-bib-0024","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1002\/ehf2.12967","article-title":"Assessment of major mental disorders in a German peripartum cardiomyopathy cohort","volume":"7","author":"Pfeffer","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200342070-00003","article-title":"Clinical pharmacokinetics of cabergoline","volume":"42","author":"Del Dotto","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026012114123349100_ehf214210-bib-0026","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/eurjhf\/hfn034","article-title":"Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy","volume":"11","author":"de Jong","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2015.03.364","article-title":"Acute peripartum cardiomyopathy rapidly evolving in cardiogenic shock","volume":"189","author":"Scardovi","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012114123349100_ehf214210-bib-0028","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/s-0036-1584567","article-title":"Peripartum cardiomyopathy treatment with dopamine agonist and subsequent pregnancy with a satisfactory outcome","volume":"38","author":"Melo","year":"2016","journal-title":"Rev Bras Ginecol Obstet"},{"key":"2026012114123349100_ehf214210-bib-0029","article-title":"Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature","volume":"29","author":"Caruso","year":"2021","journal-title":"Case Rep Womens Health"},{"key":"2026012114123349100_ehf214210-bib-0030","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ejhf.882","article-title":"Peripartum cardiomyopathy in Denmark: A retrospective, population-based study of incidence, management and outcome","volume":"19","author":"Ersboll","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114123349100_ehf214210-bib-0031","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bcpt.12307","article-title":"Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels","volume":"116","author":"Krysiak","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026012114123349100_ehf214210-bib-0032","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: A systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14210","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/465\/65108104\/eschf_10_1_465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/1\/465\/65108104\/eschf_10_1_465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:14:12Z","timestamp":1769022852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/1\/465\/8304979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14210","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"2022-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}